Saturday, January 07, 2023 2:47:49 PM
Doc it's sad that our FDA can't be more like the British and agree to a price for sale in compassionate use, perhaps for commercial use as well. It should be clear that the cost of commercial production should be lower than the cost of making trial product, so if they'd agree to a commercial price up front charging the same for compassionate use certainly wouldn't have nearly a great a profit, though they might make a small profit.
Our FDA wants companies to provide them the data on what the costs are in order to charge for compassionate care products, the results are that companies aren't willing to provide that information so they either provide the product for free, or don't supply it at all. Most choose not to supply it at all. In short, it's simply a nice sounding program here, but it's not working.
I think you're right about what the price will be in the U.K. post approval, essentially the same as under compassionate use, but now it will be paid for through their medical plans. I cannot say if patients pay some percentage, or not, and the same would apply here depending on your insurance plan.
Gary
Our FDA wants companies to provide them the data on what the costs are in order to charge for compassionate care products, the results are that companies aren't willing to provide that information so they either provide the product for free, or don't supply it at all. Most choose not to supply it at all. In short, it's simply a nice sounding program here, but it's not working.
I think you're right about what the price will be in the U.K. post approval, essentially the same as under compassionate use, but now it will be paid for through their medical plans. I cannot say if patients pay some percentage, or not, and the same would apply here depending on your insurance plan.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
